Anti Cancer Medication

Approx. Rs 2,700 / VialGet Latest Price

Additional Information:

Approx. Rs 15,305 / VialGet Latest Price

• (1 month) 
• Lyophilized
• For I.M. use
• For single use only

Additional Information:

Approx. Rs 6,800 / BoxGet Latest Price

Approx. Rs 400 / PieceGet Latest Price

Approx. Rs 2,775 / VialGet Latest Price

Approx. Rs 5,850 / VialGet Latest Price

Additional Information:

Approx. Rs 950 / VialGet Latest Price

Additional Information:

Approx. Rs 12,200 / VialGet Latest Price

• Nanosomal Docetaxel for Intravenous Infusion use only.

Additional Information:

Approx. Rs 1,400 / VialGet Latest Price

Approx. Rs 43,300 / VialGet Latest Price

Additional Information:

Approx. Rs 14,500 / VialGet Latest Price

• 1 vial of 16 ml concentrate for solution for intravenous infusion
• 1vial of 4 ml concentrate for solution for intravenous infusion
• For intravenous administration after dilution.

Additional Information:

Approx. Rs 16,000 / VialGet Latest Price

Mozobil (plerixafor) injection is a sterile, preservative-free, clear, colorless to pale-yellow, isotonic solution for subcutaneous injection. Each mL of the sterile solution contains 20 mg of plerixafor. Each single-use vial is filled to deliver 1.2 mL of the sterile solution that contains 24 mg of plerixafor and 5.9 mg of sodium chloride in Water for Injection adjusted to a pH of 6.0 to 7.5 with hydrochloric acid and with sodium hydroxide, if required.

Plerixafor is a hematopoietic stem cell mobilizer with a chemical name l, 1’-[1,4phenylenebis(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane. It has the molecular formula C28H54N8. The molecular weight of plerixafor is 502.79 g/mol.

Mozobil®(plerixafor) injection is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).

Vials should be inspected visually for particulate matter and discoloration prior to administration and should not be used if there is particulate matter or if the solution is discolored.

Begin treatment with Mozobil after the patient has received G-CSF once daily for four days [see Recommended Concomitant Medications]. Administer Mozobil approximately 11 hours prior to initiation of each apheresis for up to 4 consecutive days.

The recommended dose of Mozobil by subcutaneous injection is based on body weight:

• 20 mg fixed dose or 0.24 mg/kg of body weight for patients weighing ≤83 kg. [see CLINICAL PHARMACOLOGY]
• 0.24 mg/kg of body weight for patients weighing >83 kg.

Use the patient’s actual body weight to calculate the volume of Mozobil to be administered. Each vial delivers 1.2 mL of 20 mg/mL solution, and the volume to be administered to patients should be calculated from the following equation:

0.012 × patient’s actual body weight (in kg) = volume to be administered (in mL)

In clinical studies, Mozobil dose has been calculated based on actual body weight in patients up to 175% of ideal body weight. Mozobil dose and treatment of patients weighing more than 175% of ideal body weight have not been investigated.

Based on increasing exposure with increasing body weight, the Mozobil dose should not exceed 40 mg/day.

Additional Information:

Approx. Rs 1,120 / VialGet Latest Price

Additional Information:

Approx. Rs 390 / VialGet Latest Price

Additional Information: